Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Hayato Okade
Institution:
Meiji Seika Pharma Co., Ltd. (Japan)
Observed institutions:
Aichi Medical University,
Meiji Seika Pharma Co., Ltd. (Japan)
ORCID:
0000-0002-2570-6056
Observed ORCID:
0000-0002-2570-6056
OpenAlex ID:
A5017657848
Pharmacodynamic evaluation of meropenem, cefepime, or aztreonam combined with a novel β-lactamase inhibitor, nacubactam, against carbapenem-resistant and/or carbapenemase-producing Klebsiella pneumoniae and Escherichia coli using a murine thigh-infection model
2021
·
Mao Hagihara
, Hideo Kato
, et al.
·
International Journal of Antimicrobial Agents
·
23
PDF
Impact of the pneumococcal conjugate vaccine on serotype distribution and susceptibility trends of pediatric non-invasive Streptococcus pneumoniae isolates in Tokai, Japan over a 5-year period
2014
·
Hayato Okade
, Tori Funatsu
, et al.
·
Journal of Infection and Chemotherapy
·
23
Impact of the pneumococcal conjugate vaccine on serotype distribution of adult non-invasive Streptococcus pneumoniae isolates in Tokai region, Japan, 2008–2016
2017
·
Yuri Furuya
, Yuka Yamagishi
, et al.
·
Journal of Infection and Chemotherapy
·
17
Characterization of plasmid-mediated quinolone resistance determinants in Klebsiella pneumoniae and Escherichia coli from Tokai, Japan
2014
·
Hayato Okade
, Satoshi Nakagawa
, et al.
·
Journal of Infection and Chemotherapy
·
17
In Vivo Pharmacodynamics of β-Lactams/Nacubactam against Carbapenem-Resistant and/or Carbapenemase-Producing Enterobacter cloacae and Klebsiella pneumoniae in Murine Pneumonia Model
2021
·
Mao Hagihara
, Hideo Kato
, et al.
·
Antibiotics
·
14
PDF
In vitro activity of aztreonam–nacubactam and cefepime–nacubactam against a global collection of clinically important Gram-negative Bacilli collected in 2021–2023
2026
·
James A Karlowsky
, Mark Estabrook
, et al.
·
JAC-Antimicrobial Resistance
·
3
In vitro activity of the novel β-lactamase inhibitor nacubactam against a nationwide collection of carbapenem-resistant Enterobacterales in Japan
2026
·
Katsunori Yanagihara
, Kazuhiro Tateda
, et al.
·
JAC-Antimicrobial Resistance
·
1
1279. In Vitro Activity of Nacubactam (OP0595) Alone and in Combination with β-Lactams against β-Lactamase-Producing Enterobacterales Isolated in Japan
2020
·
Yu Nagira
, Keiko Yamada
, et al.
·
Open Forum Infectious Diseases
·
1
PDF
In vitro activities of aztreonam/nacubactam and cefepime/nacubactam against a global collection of molecularly characterized Enterobacterales isolates carrying carbapenemases: a global antimicrobial resistance surveillance study from 2021 to 2023
2026
·
Mark Estabrook
, Eisuke Suzuki
, et al.
·
JAC-Antimicrobial Resistance
Sensitivity surveillance of Pseudomonas aeruginosa isolates for several antibacterial agents in Chubu area (2013-2014).
2016
·
Ai Kakumoto
, Hayato Okade
, et al.
·
PubMed
Show more works
View as search
Works count:
10
Citation count:
99
H-index:
5
I10-index:
5
Year
Topic
Type